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Open access under CC BThree stable silanetriols with increasing steric protection of the silicon atom have been tested for inhibi-
tion of acetylcholinesterase (AChE). For all tested silanetriols we found reversible inhibition of the AChE
activity at a 100 lM concentration. The highest inhibition rate was found for the sterically least hindered
cyclohexylsilanetriol with 45% inhibition relative to galanthamine hydrobromide for which an IC50 value
of 121 ± 3 lMwas determined as well. The cytotoxicity of the silanetriols used was found to be negligible
at concentrations relevant for inhibition.
 2010 Elsevier Ltd. Open access under CC BY-NC-ND license.The dominance of the element carbon in the chemistry of the
living world contrasting the prevalence of silicon in the inanimate
lithosphere has inspired chemists to search for bioactive silicon
compounds. One general access to bioactive silicon compounds is
the replacement of selected carbon atoms with silicon in known
pharmaceuticals which is also referred to as carbon/silicon switch
strategy.1,2 Siladrugs, pro-drugs and odorants have been developed
following this approach.1–6 Recently, also silicon compounds mim-
icking transition states occurring in the metabolism of organic
substrates have been very successfully employed for the inhibition
of hydrolytic enzymes.7–13 Interestingly, the silanediols
(R2Si(OH)2) used for this purpose normally have no stable organic
counterpart (R2C(OH)2) according to Erlenmeyers rule.14,15 There-
fore they are touching the border between bioactive silicon com-
pounds derived from organic lead structures and those for which
there are no carbon analogs like, for example, silatranes16–19 and
the phtalocyanine Pc4.20,21
Inspired by the work of Sieburth and co-workers concerned
with silanediols, it seems obvious that silanetriols (R–Si(OH)3), in
which even more silanol functions are attached to the same silicon
atom, could be a mimic for hydrated transition states occurring in
the hydrolytic cleavage of carboxylic acid derivatives (Scheme 1).
In an earlier report the functional group –Si(OH)3 has already been
tested for inhibition of a serine hydrolase but no signiﬁcant activity
had been observed.22 One issue raised by the authors conducting
this study was the instability of the speciﬁc silanetriol under inves-
tigation toward condensation, which might be the actual reason forx: +43 316 380 9835.
ietschnig).
Y-NC-ND license.its poor activity. Based on our own experience with the chemistry
of silanetriols,23–27 we wondered whether an improved stability of
the silanetriol might also give rise to its inhibitory activity. Conse-
quently, we investigated the activity of some stable silanetriols
(R–Si(OH)3, R = i-pentyl, c-hexyl, 2,6-dimesitylphenyl) as novel
inhibitors for the hydrolytic enzyme acetylcholinesterase (AChE).
There is general interest in choline esterase inhibitors because they
may be used in the treatment of Alzheimer’s disease.28
Three simple silanetriols (R–Si(OH)3, R = i-pentyl (1),29 c-hexyl
(2), 2,6-dimesitylphenyl (3),23 Scheme 2) differing in their steric
environment and ﬂexibility around the functional group have been
tested for their inhibitory activity using a modiﬁed version of the
colorimetric method of Ellman.30 The enzyme acetylcholinesterase
hydrolyzes the substrate acetylthiocholine with formation of
thiocholine. The thiocholine reacts with Ellman’s reagent
(5,50-dithio-bis(2-nitrobenzoic acid; DTNB) to produce 2-nitro-
benzoate-5-mercaptothiocholine and 5-thio-2-nitrobenzoate
which can be detected photometrically at 405 nm.
For all tested silanetriols 1–3 we found inhibition of the AChE
activity (Fig. 1). The highest inhibition rate was observed for cyclo-
hexyl substituted silanetriol (2) with 45% relative inhibition
(100 lM). Signiﬁcantly lower inhibition rates have been observedScheme 1. Isolobal resemblance of a silanetriol with the tetrahedral hydrolysis
intermediate of a carboxylic ester.
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Figure 2. Graphical representation of the IC50 determination of the inhibition on
acetylcholinesterase of 2. Four different concentrations (ranging from 30 to
300 lM) were tested. Data are represented as inhibition in % of solvent control
and are expressed as mean values ± standard deviation of at least eight independent
experiments.
Scheme 2. Chemical structures of silanetriols 1–3 used in this inhibition study.
364 M. Blunder et al. / Bioorg. Med. Chem. Lett. 21 (2011) 363–365for 1 and 3with 10% and 12% relative inhibition, respectively. Com-
pound 2 as the most active in this series was used for a determina-
tion of an IC50 value. With respect to the highest activity after
15 min (vi) we have chosen this point for the determination of
the IC50 value. Four different concentrations ranging from 30 to
300 lM were used for establishing a dose response curve and re-
sults have been evaluated with the SIGMAPLOT program package.
The sigmoidal 4-parameter logistics curve was used for data ﬁtting
yielding an IC50 value of 121 ± 3 lM for silanetriol 2. A graphical
representation of the IC50 curve clearly showing a dose dependent
inhibitory effect is illustrated in Figure 2.
Compounds 1–3 are members of a simple yet pharmacologically
completely unexplored substance class. Therefore the obtained
inhibition values ranging from 10% to 45% are quite promising
compared to the positive control galanthamine hydrobromide
which was tested at the same concentration (100 lM). Galantha-
mine is an alkaloid which occurs naturally in various plant species
of Galanthus and Narcissus (Amaryllidaceae family). It is a known
reversible inhibitor of cholinesterase activity.31 From their chemi-
cal structure and their synthetic accessibility and variability sila-
netriols 1–3 are extremely simple compared to galanthamine.
The signiﬁcantly lower inhibition values for 1 and 3 are particu-
larly interesting since in this study these two silanetriols are the
more sterically shielded ones while 2 is the least hindered conge-
ner. Consequently there should be an optimum size for the substi-
tuent adjacent to the –Si(OH)3 group which renders steric
protection to the functional group against condensation, yet leaves
room to access the active site of the enzyme.
An important aspect of inhibition of the AChE activity is the
reversibility of the inhibition. Certain inhibitors like phosphoric
acid derivatives formerly used as insecticides or chemical warfareFigure 1. Comparison of the inhibitory activity of 1–3 in % after 15 min in relation
to galanthamine hydrobromide as positive control. Compounds and control were
tested at a ﬁnal concentration of 100 lM. Data are expressed as % of solvent control
as mean values ± SEM of at least eight independent experiments.agents may lead to an irreversible phosphorylation of the serine
OH group of the active site of AChE and eventually to the destruc-
tion of the enzyme.32–35
Therefore, we also investigated the time dependence of the
inhibition activity (Fig. 3). As it turns out the inhibition of AChE
by silanetriols 1–3 is not irreversible. As can be seen in Figure 3
for 2 and 3, there is a continuous decay of the enzyme inhibition
with time which rules out an irreversible silylation of the serine
OH group as was suggested for a related serine hydrolase.22 The
reversible character of this inhibition during which the enzyme re-
mains intact is also an important prerequisite for a potential use of
silanetriols as a therapeutic drug.
To analyze, whether the tested silanetriols 1–3 show a nonspe-
ciﬁc (re)activity in human cells—associated with cytotoxicity—we
performed an XTT proliferation assay to investigate the cell viabil-
ity after treatment with the respective compounds. The human
fetal lung ﬁbroblast cell line (MRC-5) was used because it is espe-
cially suited for preliminary estimates of cytotoxicity for humans.
At three different points in time (1, 15 and 41 h) cell viability
was examined by adding XTT solution to measure the metabolic
activity of viable cells. This XTT cell proliferation assay is based
on the cleavage of the yellow 2,3-bis[2-methoxy-4-nitro-5-sulf-
ophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) by ubiq-
uitous dehydrogenases leading to the formation of an orange
formazan dye. The amount of dye is proportional to the numberFigure 3. Time dependent inhibitory effect on acetylcholinesterase activity for 2
and 3. Activity is referred to solvent control and data are shown as mean
values ± SEM of at least eight independent experiments.
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Figure 4. Cell viability of MRC-5 cells measured by using XTT proliferation assay after incubation with different concentrations of the respective compounds or control for
15 h. Conversion into the measured dye is allowed to proceed for 4 h. Viability is referred to cells treated with solvent solely (control). Data are shown as mean values ± SEM
of at least six independent experiments.
M. Blunder et al. / Bioorg. Med. Chem. Lett. 21 (2011) 363–365 365of metabolic active cells and can be quantiﬁed photometrically by
differential measurement at two wavelengths. No signiﬁcant cyto-
toxicity of compounds 1–3was found for this human cell line, even
after incubation for almost 45 h (data not shown). The cell viability
of all tested compounds after 15 h incubation time is displayed in
Figure 4.
In summary, three stable silanetriols 1–3 with increasing steric
protection of the silicon atom have been tested for inhibition of
acetylcholinesterase (AChE). For all tested silanetriols we found
inhibition of the AChE activity at a 100 lM concentration. The
highest inhibition rate was found for the sterically least hindered
(2) with 45% inhibition in relation to galanthamine hydrobromide
for which an IC50 value of 121 ± 3 lM was determined. The cyto-
toxicity of these compounds at the inhibition concentration was
assessed using a human fetal lung ﬁbroblast cell line and was neg-
ligible even at substantially higher silanetriol concentrations. Apart
from their potential use in pharmaceutical therapy, the activity of
silanetriols in the inhibition of hydrolytic enzymes is generally rel-
evant because they may occur as metabolites of cyclic siloxanes
like D4 in mammals.36 Although such cyclic siloxanes are widely
used in personal care products etc. detrimental effects of their
metabolites are not likely owing to the extremely low concentra-
tions that can be expected, based on a recent assessment of the
maximum plausible daily exposure of the population in Canada
to cyclic siloxanes.37,38 According to the latter report, the concen-
tration of silanetriol metabolites can be expected to be by orders
of magnitude lower than the ﬁnal concentrations of 1–3 used in
our inhibition experiments which were 100 lM. Furthermore, the
reversible binding to the active site of the enzyme will prevent
irreversible enzyme damage. In future work we will aim to im-
prove the inhibitory effect by structural variation of the adjacent
organic substituent of the silanetriol.
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